Roger Brauninger, BioSafety Program Manager, at American Association for Laboratory Accreditation (A2LA), sat down with us at CannaWest 2018 and shared his insights on various topics within cannabis lab testing. We also asked how he sees the professionalism level of dedicated cannabis testing labs improving over the last 3 years and what areas he thinks still need more attention. See what he has to say…
Roger Brauninger, BioSafety Program Manager, American Association for Laboratory Accreditation
Filmed By: Jen Neville
July 20, 2018
Q&A with Roger Brauninger
BioSafety Program Manager
The opportunity for operators in the canna space is startling. Estimates suggest that the combined medical and adult-use market may be worth $5 billion by 2019 in California alone, while the forecasts for national and global canna markets are revised, upward, on a daily basis. The demonstrated ability of cannabis use to lower America’s $12 billion-plus opioid drug tab suggests that those estimates may be conservative. However, in order to take advantage of this remarkable opportunity to do good and do well, industry players must navigate a new and evolving regulatory framework.
The introduction of regulation in the space has created novel challenges in order to ensure product safety, manage liability and deliver efficacy for every part of the canna supply chain. To take just one example: testing labs suggest that 80% of California-produced cannabis still tests positive for pesticides, which has resulted in the scheduled introduction of mandatory testing in the state starting in July 2018.
State regulators and health officials—in unmatched numbers—shared notes and driving operators towards uniform testing, labeling, operational standards, protocols and best practices.